益生菌对非酒精性脂肪肝患者肝酶、肥胖指数、血压、血脂谱和炎症的影响：系统评价和随机对照试验的荟萃分析。

The effect of synbiotics on liver enzymes, obesity indices, blood pressure, lipid profile, and inflammation in patients with non-alcoholic fatty liver: A systematic review and meta-analysis of randomized controlled trials.

机构信息

Student Research Committee, School of Public Health, Iran University of Medical Sciences, Tehran, Iran; Department of Nutrition, School of Public Health, Iran University of Medical Sciences, Tehran, Iran.

Medical School, University of Pécs, Pécs, Hungary.

出版信息

Pharmacol Res. 2024 Oct;208:107398. doi: 10.1016/j.phrs.2024.107398. Epub 2024 Sep 4.

DOI:10.1016/j.phrs.2024.107398

PMID:39241935

Abstract

BACKGROUND

Patients with non-alcoholic fatty liver disease (NAFLD) benefit from using synbiotics. However, findings from existing trials remain contentious. Therefore, this meta-analysis evaluated the effects of synbiotics on liver enzymes, blood pressure, inflammation, and lipid profiles in patients with NAFLD.

METHODS

We searched PubMed, Embase, Cochrane, Scopus, and Web of Science for randomized controlled trials (RCTs) regarding synbiotics supplementation in patients with NAFLD.

RESULTS

The meta-analysis revealed that synbiotics supplementation significantly improved liver enzymes (AST, WMD: -9.12 IU/L; 95 % CI: -13.19 to -5.05; ALT, WMD: -8.53 IU/L; 95 % CI: -15.07 to -1.99; GGT, WMD: -10.42 IU/L; 95 % CI: -15.19 to -5.65), lipid profile (TC, WMD: -7.74 mg/dL; 95 % CI: -12.56 to -2.92), obesity indices (body weight, WMD: -1.95 kg; 95 % CI: -3.69 to -0.22; WC, WMD: -1.40 cm; 95 % CI: -2.71 to -0.10), systolic blood pressure (SBP, WMD: -6.00 mmHg; 95 % CI: -11.52 to -0.49), and inflammatory markers (CRP, WMD: -0.69 mg/L; 95 % CI: -1.17 to -0.21; TNF-α, WMD: -14.01 pg/mL; 95 % CI: -21.81 to -6.20).

CONCLUSION

Overall, supplementation with synbiotics positively improved liver enzymes, obesity indices, and inflammatory cytokines in patients with NAFLD.

摘要

背景

非酒精性脂肪性肝病 (NAFLD) 患者受益于使用合生剂。然而，现有试验的结果仍存在争议。因此，本荟萃分析评估了合生剂对 NAFLD 患者肝酶、血压、炎症和血脂谱的影响。

方法

我们检索了 PubMed、Embase、Cochrane、Scopus 和 Web of Science 中关于合生剂补充治疗 NAFLD 患者的随机对照试验 (RCT)。

结果

荟萃分析显示，合生剂补充治疗可显著改善肝酶 (AST，WMD：-9.12 IU/L；95%CI：-13.19 至 -5.05；ALT，WMD：-8.53 IU/L；95%CI：-15.07 至 -1.99；GGT，WMD：-10.42 IU/L；95%CI：-15.19 至 -5.65)、血脂谱 (TC，WMD：-7.74mg/dL；95%CI：-12.56 至 -2.92)、肥胖指数 (体重，WMD：-1.95kg；95%CI：-3.69 至 -0.22；WC，WMD：-1.40cm；95%CI：-2.71 至 -0.10)、收缩压 (SBP，WMD：-6.00mmHg；95%CI：-11.52 至 -0.49) 和炎症标志物 (CRP，WMD：-0.69mg/L；95%CI：-1.17 至 -0.21；TNF-α，WMD：-14.01pg/mL；95%CI：-21.81 至 -6.20)。